Advances in the development of therapeutic nucleic acids against cervical cancer

Bibliography

• PISANI P, BRAY F, PARKIN DM: Estimates of the worldwide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer (2002) 97:72–81.
   PubMed Web of Science ®Google Scholar
• CLIFFORD GM, SMITH JS, PLUMMER M, MUNOZ N, FRANCESCHI S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer (2003) 88:63–73.
   PubMed Web of Science ®Google Scholar
• ZUR HAUSEN H: Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta (1996) 1288:F55–F78.
   PubMed Web of Science ®Google Scholar
• ZUR HAUSEN H: Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin. Cancer Biol. (1999) 9:405–411.
   PubMed Web of Science ®Google Scholar
• LAMBERT PF, DOSTATNI N, MCBRIDE AA, YANIV M, HOWLEY PM, ARCANGIOLI B: Functional analysis of the papilloma virus E2 transactivator in Saccharomyces cerevhiae. Genes Dev. (1989) 3:38–48.
   PubMed Web of Science ®Google Scholar
• CHIANG CM, USTAV M, STENLUND A, HO TF, BROKER TR, CHOW LT: Viral El and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc. Nati Acad. Sci. USA (1992) 89:5799–5803.
   PubMed Web of Science ®Google Scholar
• KUO SR, LIU JS, BROKER TR, CHOW LT: Cell-free replication of the human papillomavirus DNA with homologous viral El and E2 proteins and human cell extracts. J. Biol. Chem. (1994) 269:24058–24065.
   PubMed Web of Science ®Google Scholar
• PIRISI L, YASUMOTO S, FELLER M, DONIGER J, DIPAOLO JA: Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J. Virol. (1987) 61:1061–1066.
   PubMed Web of Science ®Google Scholar
• DURST M, DZARLIEVA-PETRUSEVSKA RT, BOUKAMP P, FUSENIG NE, GISSMANN L: Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene (1987) 1:251–256.
   PubMed Web of Science ®Google Scholar
• BROKER TR: Structure and genetic expression of papillomaviruses. Obstet. Cynecol Clin. North Am. (1987) 14:329–348.
   PubMed Web of Science ®Google Scholar
• WERNESS BA, LEVINE AJ, HOWLEY PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 248:76–79.
   PubMed Web of Science ®Google Scholar
• SCHEFFNER M, WERNESS BA, HUIBREGTSE JM, LEVINE AJ, HOWLEY PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 63:1129–1136.
   PubMed Web of Science ®Google Scholar
• HUIBREGTSE JM, SCHEFFNER M, HOWLEY PM: A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. (1991) 10:4129–4135.
   PubMed Web of Science ®Google Scholar
• HUIBREGTSE JM, SCHEFFNER M, HOWLEY PM: Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53 and ubiquitylation of associated proteins. Ma Cell. Biol. (1993) 13:4918–4927.
   Web of Science ®Google Scholar
• KLINGELHUTZ AJ, FOSTER SA, MCDOUGALL JK: Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature (1996) 380:79–82.
   PubMed Web of Science ®Google Scholar
• GEWIN L, GALLOWAY DA: E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. Vim/. (2001) 75:7198–7201.
   Web of Science ®Google Scholar
• OH ST, KYO S, LAIMINS LA: Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Spl binding sites. I. Vim/. (2001) 75:5559–5566.
   Google Scholar
• GARDIOL D, KUHNE C, GLAUNSINGER B, LEE SS, JAVIER R, BANKS L: Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene (1999) 18:5487–5496.
   PubMed Web of Science ®Google Scholar
• LEE SS, GLAUNSINGER B, MANTOVANI F, BANKS L, JAVIER RT: Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. Virol (2000) 74:9680–9693.
   Web of Science ®Google Scholar
• GLAUNSINGER BA, LEE SS, THOMAS M, BANKS L, JAVIER R: Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene (2000) 19:5270–5280.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN H, DEGENKOLBE R, BERNARD HU, O'CONNOR MJ: The human papillomavirus type 16 E6 oncoprotein can downregulate p53 activity by targeting the transcriptional co-activator CBP/p300. Virol. (1999) 73:6209–6219.
   Web of Science ®Google Scholar
• ETSCHEID BG, FOSTER SA, GALLOWAY DA: The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumour suppressor protein, p53. Virology (1994) 205:583–585.
   PubMed Web of Science ®Google Scholar
• MUNGER K, BASILE JR, DUENSING S et al.: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene (2001) 20:7888–7898.
   PubMed Web of Science ®Google Scholar
• DYSON N, HOWLEY PM, MUNGER K, HARLOW E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 243:934–937.
   PubMed Web of Science ®Google Scholar
• DUENSING S, DUENSING A, FLORES ER, DO A, LAMBERT PF, MUNGER K: Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. Virol (2001) 75:7712–7716.
   Web of Science ®Google Scholar
• MUNGER K, PHELPS WC: The human papillomavirus E7 protein as a transforming and transactivating factor. Biochim. Biophys. Acta (1993) 1155:111–123.
   PubMed Web of Science ®Google Scholar
• BOYER SN, WAZER DE, BAND V: E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. (1996) 56:4620–4624.
   PubMed Web of Science ®Google Scholar
• BEREZUTSKAYA E, YU B, MOROZOV A, RAYCHAUDHURI P, BAGCHI S: Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Diller. (1997) 8:1277–1286.
   PubMedGoogle Scholar
• DIPAOLO JA, POPESCU NC, ALVAREZ L, WOODWORTH CD: Cellular and molecular alterations in human epithelial cells transformed by recombinant human papillomavirus DNA. Crit. Rev Oncog. (1993) 4:337–360.
   PubMed Web of Science ®Google Scholar
• DUENSING S, MUNGER K: The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. (2002) 62:7075–7082.
   PubMed Web of Science ®Google Scholar
• SMOTKIN D, PROKOPH H, WETTSTEIN FO: Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. Vim/. (1989) 63:1441–1447.
   Web of Science ®Google Scholar
• SCHNEIDER-GADICKE A, SCHWARZ E: Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J. (1986) 5:2285–2292.
   PubMed Web of Science ®Google Scholar
• BUTZ K, DENK C, ULLMANN A, SCHEFFNER M, HOPPE-SEYLER F: Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. USA (2000) 97:6693–6697.
   PubMed Web of Science ®Google Scholar
• ALVAREZ-SALAS LM, CULLINAN AE, SIWKOWSKI A, HAMPEL A, DIPAOLO JA: Inhibition of HPV-16 E6/ E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc. Natl. Acad. Sci. USA (1998) 95:1189–1194.
   PubMed Web of Science ®Google Scholar
• ••First report on the in vivo activity ofhairpin RZs for cervical cancer.
   Google Scholar
• ALVAREZ-SALAS LM, ARPAWONG TE, DIPAOLO JA: Growth inhibition of cervical tumour cells by antisense oligodeoxynucleotides directed to the human papillomavirus type 16 E6 gene. Antisense Nucleic Acid Drug Dev. (1999) 9:441–450.
   PubMedGoogle Scholar
• MOSER HE, DERVAN PB: Sequence-specific cleavage of double helical DNA by triple helix formation. Science (1987) 238:645–650.
   PubMed Web of Science ®Google Scholar
• LETAI AG, PALLADINO MA, FROMM E, RIZZO V, FRESCO JR: Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns. Biochemistry (1988) 27:9108–9112.
   PubMed Web of Science ®Google Scholar
• EBBINGHAUS SW, FORTINBERRY H, GAMPER HBJ: Inhibition of transcription elongation in the HER-2/neu coding sequence by triplex-directed covalent modification of the template strand. Biochemistry (1999) 38:619–628.
   PubMed Web of Science ®Google Scholar
• CARBONE GM, MCGUFFIE EM, COLLIER A, CATAPANO CV: Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide. Nucleic Acids Res. (2003) 31:833–843.
   PubMed Web of Science ®Google Scholar
• VASQUEZ KM, GLAZER PM: Triplex-forming oligonucleotides: principles and applications. Q. Rev Biophys. (2002) 35:89–107.
   PubMed Web of Science ®Google Scholar
• MALKOV VA, VOLOSHIN ON, SOYFER VN, FRANK-KAMENETSKII MD: Cation and sequence effects on stability of intermolecular pyrimidine-purine-purine triplex. Nucleic Acids Res. (1993) 21:585–591.
   PubMed Web of Science ®Google Scholar
• CHERNY DI, MALKOV VA, VOLODIN AA, FRANK-KAMENETSKII MD: Electron microscopy visualization of oligonucleotide binding to duplex DNA via triplex formation.Biol. (1993)230:379–383.
   Google Scholar
• POPA LM, SCHUTZ H, WINTERS, KITTLER L, LOBER G: Specific targeting of human papillomavirus type 16 E7 oncogene with triple-helix forming purine oligodeoxyribonucleotides. Biochem. MM. Biol. hat. (1996) 38:285–295.
   PubMed Web of Science ®Google Scholar
• BONHAM MA, BROWN S, BOYD AL et al.: An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Adds Res. (1995) 23:1197–1203.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, ZHANG R: Pharmacokinetics of oligonucleotides. CIBA Found. Symp. (1997) 209:60–75.
   PubMedGoogle Scholar
• WAGNER RW, MATTEUCCI MD, LEWIS JG, GUTIERREZ AJ, MOULDS C, FROEHLER BC: Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science (1993) 260:1510–1513.
   PubMed Web of Science ®Google Scholar
• BENNETT CF: Antisense oligonucleotides: is the glass half full or half empty? Biochem. Pharmacol (1998) 55:9–19.
   Web of Science ®Google Scholar
• MERCATANTE D, KOLE R: Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol Ther. (2000) 85:237–243.
   PubMed Web of Science ®Google Scholar
• SIERAKOWSKA H, GORMAN L, KANG SH, KOLE R: Antisense oligonucleotides and RNAs as modulators of premRNA splicing. Methods Enzymol (2000) 313:506–521.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, ZHAO Q: Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Add Drug Dev. (1998) 8:135–139.
   PubMedGoogle Scholar
• STERNBERGER M, SCHMIEDEKNECHT A, KRETSCHMER A et al.: GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation. Antisense Nucleic Acid Drug Dev. (2002) 12:131–143.
   PubMedGoogle Scholar
• VON KNEBEL DOEBERITZ M, OLTERSDORF T, SCHWARZ E, GISSMANN L: Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res. (1988) 48:3780–3786.
   PubMed Web of Science ®Google Scholar
• ••First AS-RNA used on cervicalcarcinoma cells.
   Google Scholar
• VON KNEBEL DOEBERITZ M, RITTMULLER C, ZUR HAUSEN H, DURST M: Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 antisense RNA. Int. J. Cancer (1992) 51:831–834.
   PubMed Web of Science ®Google Scholar
• CHO CW, POO H, CHO YS et al.: HPVE6 antisense induces apoptosis in CaSki cells via suppression of E6 splicing. Exp. Md. Med. (2002) 34:159–166.
   PubMed Web of Science ®Google Scholar
• CHOO CK, LING MT, SUEN CK, CHAN KW, KWONG YL: Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol °fled. (2000) 78:293–301.
   PubMed Web of Science ®Google Scholar
• HAYASHI S, NAGASAKA T, KATAYAMA A et al.: Adenovirus-mediated gene transfer of antisense ribozyme for alpha (1,3)galactosyltransferase gene and alpha (1,2)fucosyltransferase gene in xenotransplantation. Transplant. Proc. (1997) 29:2213–2213.
   PubMed Web of Science ®Google Scholar
• STEELE C, COWSERT LM, SHILLITOE EJ: Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Res. (1993) 53:2330–2337.
   PubMed Web of Science ®Google Scholar
• ••First use of AS-ODNs against HPV.
   Google Scholar
• TAN TM, TING RC: In vitro and M vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res. (1995) 55:4599–4605.
   PubMed Web of Science ®Google Scholar
• ••Initial in vivo use of AS-ODNs for cervicalcancer treatment.
   Google Scholar
• KRONENWETT R, SCZAKIEL G: Selection of fast-hybridizing complementary RNA species M vitro. Methods MM. Biol. (1997) 74:281–288.
   PubMedGoogle Scholar
• VENTURINI F, BRASPENNING J, HOMANN M, GISSMANN L, SCZAKIEL G: Kinetic selection of HPV 16 E6 /E7-directed antisense nucleic acids: antiproliferative effects on HPV 16-transformed cells. Nucleic Acids Res. (1999) 27:1585–1592.
   PubMed Web of Science ®Google Scholar
• ••Experimental confirmation of HPV-16`antisense window'.
   Google Scholar
• HASELOFF J, GERLACH WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (1988) 334:585–591.
   PubMed Web of Science ®Google Scholar
• HAMPEL A, TRITZ R: RNA catalytic properties of the minimum (-)sTRSV sequence. Biochemistry (1989) 28:4929–4933.
   PubMed Web of Science ®Google Scholar
• ROSSI JJ: Ribozymes. Cum Opin. Biotechnol (1992) 3:3–7.
   Google Scholar
• ECKSTEIN F, KORE AR, NAKAMAYE KL: In vitro selection of hammerhead ribozyme sequence variants. Chembiochem (2001) 2:629–635.
   PubMed Web of Science ®Google Scholar
• CECH TR: Self-splicing of group I introns. Anna. Rev Biochem. (1990) 59:543–568.
   PubMed Web of Science ®Google Scholar
• GUERRIER-TAKADA C, GARDINER K, MARSH T, PACE N, ALTMAN S: The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell (1983) 35:849–857.
   PubMed Web of Science ®Google Scholar
• HASELOFF J, GERLACH WL: Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus. Gene (1989) 82:43–52.
   PubMed Web of Science ®Google Scholar
• HUTCHINS CJ, RATHJEN PD, FORSTER AC, SYMONS RH: Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Adds Res. (1986) 14:3627–3640.
   PubMed Web of Science ®Google Scholar
• LATHAM JA, ZAUG AJ, CECH TR: Self-splicing and enzymatic cleavage of RNA by a group I intervening sequence. Methods Enzymol (1990) 181:558–569.
   PubMed Web of Science ®Google Scholar
• CECH TR, HERS CHLAG D, PICCIRILLI JA, PYLE AM: RNA catalysis by a group I ribozyme. Developing a model for transition state stabilization. Biol. Chem. (1992) 267:17479–17482.
   Google Scholar
• SAVILLE BJ, COLLINS RA: A site-specific self-cleavage reaction performed by a novel RNA in Neurospora mitochondria. Cell (1990) 61:685–696.
   PubMed Web of Science ®Google Scholar
• BRANCH AD, ROBERTSON HD: Efficient trans cleavage and a common structural motif for the ribozymes of the human hepatitis delta agent. Proc. Nati Acad. Sci. USA (1991) 88:10163–10167.
   PubMed Web of Science ®Google Scholar
• KRUGER K, GRABOWSKI PJ, ZAUG AJ, SANDS J, GOTTSCHLING DE, CECH TR: Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervining sequence of Tetrahymena. Cell (1982) 31:147–157.
   PubMed Web of Science ®Google Scholar
• ROSSI JJ: Practical ribozymes. Making ribozymes work in cells. Cum Biol. (1994) 4:469–471.
   Google Scholar
• SYMONS RH: Small catalytic RNAs. Annu. Rev. Biochem. (1992) 61:641–671.
   PubMed Web of Science ®Google Scholar
• PAVCO PA, BOUHANA KS, GALLEGOS AM et al.: Antitumour and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. (2000) 6:2094–2103.
   PubMed Web of Science ®Google Scholar
• MORRISSEY DV, LEE PA, JOHNSON DA et al: Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. .1. Viral Hepat. (2002) 9:411–418.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ C, DAROS JA, ELENA SF, MOYA A, FLORES R: The strands of both polarities of a small circular RNA from carnation self-cleave M vitro through alternative double- and single-hammerhead structures. Nucleic Acids Res. (1992) 20:6323–6329.
   PubMed Web of Science ®Google Scholar
• NAVARRO B, FLORES R: Chrysanthemum chlorotic mottle viroid: unusual structural properties of a subgroup of self-cleaving viroids with hammerhead ribozymes. Proc. Nati Acad. Sci. USA (1997) 94:11262–11267.
   PubMed Web of Science ®Google Scholar
• FORSTER AC, SYMONS RH: Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell (1987) 49:211–220.
   PubMed Web of Science ®Google Scholar
• EPSTEIN LM, GALL JG: Self-cleaving transcripts of satellite DNA from the newt. Cell (1987) 48:535–543.
   PubMed Web of Science ®Google Scholar
• VAISH NK, KORE AR, ECKSTEIN F: Recent developments in the hammerhead ribozyme field. Nucleic Acids Res. (1998) 26:5237–5242.
   PubMed Web of Science ®Google Scholar
• KORE AR, VAISH NK, KUTZKE U, ECKSTEIN F: Sequence specificity of the hammerhead ribozyme revisited; the NHH rule. Nucleic Acids Res. (1998) 26:4116–4120.
   PubMed Web of Science ®Google Scholar
• UHLENBECK OC: A small catalytic oligoribonucleotide. Nature (1987) 328:596–600.
   PubMed Web of Science ®Google Scholar
• SHELDON CC, SYMONS RH: Mutagenesis analysis of a self-cleaving RNA. Nucleic Acids Res. (1989) 17:5679–5685.
   PubMed Web of Science ®Google Scholar
• PRODY GA, BAKOS JT, BUZAYAN JM,SCHNEIDER IR, BRUENING G: Autolytic processing of dimeric plant virus satellite RNA. Science (1986) 321:1577–1580.
   Google Scholar
• HAMPEL A: The hairpin ribozyme: discovery, two-dimensional model and development for gene therapy. Frog. Nucleic Acid Res. Md. Biol. (1998) 58:1–39.
   PubMed Web of Science ®Google Scholar
• YU Q, BURKE JM: Design of hairpin ribozymes for in vitro and cellular applications. Methods MM. Biol. (1997) 74:161–169.
   PubMedGoogle Scholar
• HAMPEL A, TRITZ R, HICKS M, CRUZ P: 'Hairpin' catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. Nucleic Adds Res. (1990) 18:299–304.
   PubMed Web of Science ®Google Scholar
• ANDERSON P, MONFORTE J, TRITZ R, NESBITT S, HEARST J, HAMPEL A: Mutagenesis of the hairpin ribozyme. Nucleic Acids Res. (1994) 22:1096–1100.
   PubMed Web of Science ®Google Scholar
• DEYOUNG M, SIWKOWSKI AM, LIAN Y, HAMPEL A: Catalytic properties of hairpin ribozymes derived from Chicory yellow mottle virus and arabis mosaic virus satellite RNAs. Biochemistry (1995) 34:15785–15791.
   PubMed Web of Science ®Google Scholar
• WISOTZKEY JD, KRIZENOSKAS A, DIANGELO S, KREIDER JW: Cleavage of cottontail rabbit papillomavirus E7 RNA with an antiE7 ribozyme. Biochem. Biophys. Res. Commun. (1993) 192:833–839.
   PubMed Web of Science ®Google Scholar
• HE YK, LU CD, QI GR: In vitro cleavage of HPV16 E6 and E7 RNA fragments by synthetic ribozymes and transcribed ribozymes from RNA-trimming plasmids. FEBS Lett. (1993) 322:21–24.
   PubMed Web of Science ®Google Scholar
• LU D, CHATTERJEE S, BRAR D, WONG KK, JR: Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Cancer Gene Tiler. (1994) 1:267–277.
   Web of Science ®Google Scholar
• CHEN Z, KAMATH P, ZHANG S, WEIL MM, SHILLITOE EJ: Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Tiler. (1995) 2:263–271.
   Web of Science ®Google Scholar
• CHOWRIRA BM, BERZAL-HERRANZ A, BURKE JM: Ionic requirements for RNA binding, cleavage and ligation by the hairpin ribozyme. Biochemistry (1993) 32:1088–1095.
   PubMed Web of Science ®Google Scholar
• ALVAREZ-SALAS LM, WILCZYNSKI SP, BURGER RA, MONK BJ, DIPAOLO JA: Polymorphism of the HPV-16 E6 gene of cervical carcinoma. Int. I Oncol. (1995) 7:261–266.
   PubMed Web of Science ®Google Scholar
• ALVAREZ-SALAS LM, BENITEZ-HESS ML, DIPAOLO JA: Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses. Antiviral Ther. (2003) 8:265–278.
   PubMed Web of Science ®Google Scholar
• ••In proof review on the use of therapeuticRZs for cervical cancer.
   Google Scholar
• FIRE A, XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE, MELLO CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391:806–811.
   PubMed Web of Science ®Google Scholar
• SHARP PA: RNAi and double-strand RNA. Genes Dev. (1999) 13:139–141.
   PubMed Web of Science ®Google Scholar
• ZAMORE PD, ARONIN N: siRNAs knock down hepatitis. Nat. Med. (2003) 9:266–267.
   PubMed Web of Science ®Google Scholar
• CAPLEN NJ, FLEENOR J, FIRE A, MORGAN RA: dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference. Gene (2000) 252:95–105.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, LENDECKEL W, TUSCHL T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. (2001) 15:188–200.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN E, CAUDY AA, HAMMOND SM, HANNON GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 409:363–366.
   PubMed Web of Science ®Google Scholar
• HAMMOND SM, CAUDY AA, HANNON GJ: Post-transcriptional gene silencing by double-stranded RNA. Nat. Rev Genet. (2001) 2:110–119.
   PubMed Web of Science ®Google Scholar
• NYKANEN A, HALEY B, ZAMORE PD: ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell (2001) 107:309–321.
   PubMed Web of Science ®Google Scholar
• HOLEN T, AMARZGUIOUI M, WIIGER MT, BABAIE E, PRYDZ H: Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. (2002) 30:1757–1766.
   PubMed Web of Science ®Google Scholar
• MIYAGISHI M, HAYASHI M, TAIRA K: Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. (2003) 13:1–7.
   PubMedGoogle Scholar
• JIANG M, MILNER J: Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene (2002) 21:6041–6048.
   PubMed Web of Science ®Google Scholar
• ••Initial report on the use of siRNAsagainst HPV-16.
   Google Scholar
• BUTZ K, RISTRIANI T, HENGSTERMANN A, DENK C, SCHEFFNER M, HOPPE-SEYLER F: siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene (2003) 22:5938–5945.
   PubMed Web of Science ®Google Scholar
• ••Apoptosis induction of HPV-18 cervicalcells with E6 siRNA.
   Google Scholar
• HALL AH, ALEXANDER KA: RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. .1 Virol. (2003) 77:6066–6069.
   PubMed Web of Science ®Google Scholar
• YOSHINOUCHI M, YAMADA T, KIZAKI M et al.: In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol. Ther. (2003) 8:762–768.
   PubMed Web of Science ®Google Scholar
• WRAIGHT CJ, WHITE PJ: Antisense oligonucleotides in cutaneous therapy. Pharmacol. Ther. (2001) 90:89–104.
   PubMed Web of Science ®Google Scholar
• DINGY, LAWRENCE CE: Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond. Nucleic Acids Res. (2001) 29:1034–1046.
   PubMed Web of Science ®Google Scholar
• BACON TA, WICKSTROM E: Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5' cap region. Oncogene Res. (1991) 6:13–19.
   PubMedGoogle Scholar
• MONIA BP, JOHNSTON JF, GEIGER T, MULLER M, FABBRO D: Antitumour activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. (1996) 2:668–675.
   PubMed Web of Science ®Google Scholar
• DEAN NM, MCKAY R, CONDON TP, BENNETT CF: Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. Biol. Chem. (1994) 269:16416–16424.
   Web of Science ®Google Scholar
• SCZAKIEL G, HOMANN M, RITTNER K: Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res. Dev. (1993) 3:45–52.
   PubMedGoogle Scholar
• MONIA BP, SASMOR H, JOHNSTON JF et al.: Sequence-specific antitumour activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Nati Acad. Sci. USA (1996) 93:15481–15484.
   PubMed Web of Science ®Google Scholar
• HO SP, BRITTON DH, STONE BA et al.: Potent antisense oligonucleotides to the human multi-drug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. (1996) 24:1901–1907.
   PubMed Web of Science ®Google Scholar
• PIERCE ML, RUFFNER DE: Construction of a directed hammerhead ribozyme library: towards the identification of optimal target sites for antisense-mediated gene inhibition. Nucleic Acids Res. (1998) 26:5093–5101.
   PubMed Web of Science ®Google Scholar
• HO SP, BRITTON DH, BAO Y, SCULLY MS: RNA mapping: selection of potent oligonucleotide sequences for antisense experiments. Methods Enzymo] (2000) 314:168–183.
   PubMed Web of Science ®Google Scholar
• CERCHIA L, HAMM J, LIBRI D, TAVITIAN B, DE F, V: Nucleic acid aptamers in cancer medicine. FEBS Lett. (2002) 528:12–16.
   PubMed Web of Science ®Google Scholar
• TUERK C, GOLD L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 249:505–510.
   PubMed Web of Science ®Google Scholar
• PAGRATIS NC, BELL C, CHANG YF et al: Potent 2'-amino- and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat. Biotechnol (1997) 15:68–73.
   PubMed Web of Science ®Google Scholar
• WANG J, JIANG H, LIU F: In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection. RNA (2000) 6:571–583.
   PubMed Web of Science ®Google Scholar
• WATERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of bc1-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. Clin. Oncol (2000) 18:1812–1823.
   Web of Science ®Google Scholar
• ROYCHOWDHURY D, LAHN M: Antisense therapy directed to protein kinase C-alpha (affinitak, LY-900003/ISIS 3521): potential role in breast cancer. Setnin. Oncol (2003) 30:30–33.
   PubMed Web of Science ®Google Scholar
• GEARY RS, HENRY SP, GRILLONE LR: Fomivirsen: clinical pharmacology and potential drug interactions. Clin. Phartnacokinet. (2002) 41:255–260.
   PubMed Web of Science ®Google Scholar
• BEER-ROMERO P, GLASS S, ROLFE M: Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene (1997) 14:595–602.
   PubMed Web of Science ®Google Scholar
• KIM Y, CAIRNS MJ, MAROUGA R, SUN LQ: E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes. Cancer Gene Then (2003) 10:707–716.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, HONGO A, KODAMA J, MIYAGI Y, YOSHINOUCHI M, KUDO T: Downregulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res. (2000) 60:760–765.
   PubMed Web of Science ®Google Scholar
• KRETSCHMER-KAZEMI FR, SCZAKIEL G: The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res. (2003) 31:4417–4424.
   PubMed Web of Science ®Google Scholar
• TUSCHL T, BORKHARDT A: Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Ma Intervent. (2002) 2:158–167.
   PubMedGoogle Scholar
• WALL NR, SHI Y: Small RNA: can RNA interference be exploited for therapy? Lancet (2003) 362:1401–1403.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY AP, MEUSE L, PHAM TT, CONKLIN DS, HANNON GJ, KAY MA: RNA interference in adult mice. Nature (2002) 418:38–39.
   PubMed Web of Science ®Google Scholar
• LEWIS DL, HAGSTROM JE, LOOMIS AG, WOLFF JA, HERWEIJER H: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. (2002) 32:107–108.
   PubMed Web of Science ®Google Scholar
• BERNARD HU, CHAN SY, DELIUS H: Evolution of papillomaviruses. Curr. Top. Microbiol Inonuno] (1994) 186:33–54.
   PubMedGoogle Scholar
• DE VILLIERS EM: Papillomavirus and HPV typing. Clin. Dertnatol (1997) 15:199–206.
   PubMed Web of Science ®Google Scholar
• DIPAOLO JA, ALVAREZ-SALAS LM: U56084090 (2000).
   Google Scholar
• DIPAOLO JA, ALVAREZ-SALAS LM: U56277980 (2001).
   Google Scholar
• HAMPEL A, DIPAOLO JA, SIWKOWSKI AM, GALASINSKI SC: U55683902 (1997).
   Google Scholar